...
首页> 外文期刊>Journal of Medicinal Chemistry >Further studies on imidazo[4,5-b] pyridine AT(1) angiotensin II receptor antagonists. Effects of the transformation of the 4-phenylquinoline backbone into 4-phenylisoquinolinone or 1-phenylindene scaffolds
【24h】

Further studies on imidazo[4,5-b] pyridine AT(1) angiotensin II receptor antagonists. Effects of the transformation of the 4-phenylquinoline backbone into 4-phenylisoquinolinone or 1-phenylindene scaffolds

机译:咪唑并[4,5-b]吡啶AT(1)血管紧张素II受体拮抗剂的进一步研究。 4-苯基喹啉骨架转化为4-苯基异喹啉酮或1-苯基茚骨架的影响

获取原文
获取原文并翻译 | 示例

摘要

The 4-phenylquinoline fragment of novel AT(1) receptor antagonists 4 based on imidazo[ 4,5-b] pyridine moiety was replaced by 4-phenylisoquinolinone (compounds 5) or 1-phenylindene (compounds 6) scaffolds to investigate the structure-activity relationships. Binding studies showed that most of the synthesized compounds display high affinity for the AT(1) receptor. Because of the in vitro high potency of carboxylic acids 5b, f, they were evaluated in permeability (in Caco-2 cells) and in pharmacokinetic studies in comparison with quinoline derivatives 4b, i, j, k. The studies showed that these compounds are characterized by rapid excretion, low membrane permeability, and low oral bioavailability. The structure optimization of the indene derivatives led to compounds 6e, f possessing interesting AT(1) receptor affinities. Optimization produced polymerizing AT(1) receptor ligand 6c, which forms a thermoreversible polymer (poly-6c) and is released from the latter by a temperature-dependent kinetics. The results suggest the possibility of developing novel polymeric prodrugs based on a new release mechanism. Finally, a set of 34 AT(1) receptor antagonists was used as a new test for the evaluation of the predictive capability of the previously published qualitative and quantitative pharmacophore models.
机译:基于咪唑并[4,5-b]吡啶部分的新型AT(1)受体拮抗剂4的4-苯基喹啉片段被4-苯基异喹啉酮(化合物5)或1-苯基茚(化合物6)支架取代,以研究结构-活动关系。结合研究表明大多数合成的化合物显示出对AT(1)受体的高亲和力。由于羧酸5b,f在体外具有较高的效能,因此与喹啉衍生物4b,i,j,k相比,对它们的渗透性(在Caco-2细胞中)和药代动力学研究进行了评估。研究表明,这些化合物的特点是排泄迅速,膜通透性低和口服生物利用度低。茚衍生物的结构优化导致化合物6e,f具有有趣的AT(1)受体亲和力。优化产生了可聚合的AT(1)受体配体6c,后者形成热可逆聚合物(poly-6c),并通过与温度有关的动力学从后者释放。结果表明基于新的释放机理开发新颖的聚合物前药的可能性。最后,一组34种AT(1)受体拮抗剂被用作评估先前发表的定性和定量药效团模型预测能力的新方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号